Company Overview and News
I recently gave an investment presentation to a group from a trade association. One question I got was: “I want to save up for a down payment. How can I do this without much risk? And I don’t want to just put my money in a bank savings account.”
GS AXP SYF
2018-09-15 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR
Credit cards that are affiliated with brands — such as American Airlines, Uber, L.L. Bean and Ikea — are suddenly amping up rewards for everyday purchases at restaurants, gas stations and grocery stores.
Fair value ~10% higher than current share price with possible short term negative triggers (e.g. dividend cut, goodwill write-off, slower equipment sales) holding back price recovery.
BHI GE GEC WAB BHGE GNE SYF AER
Last week, General Electric Company (NYSE:GE) hit a terrible milestone. The shares broke below $12, which was the lowest since the depths of the financial crisis in 2009. The market value on General Electric stock is now at $107 billion.
BHI GE GEC BHGE GNE UTX SYF
U.S. stocks moved mostly higher in early trading Monday, adding to the market's upbeat finish last week amid signs of progress in resolving the trade dispute between the U.S. and China. Gains in banks, health care and industrial companies outweighed losses in technology stocks. Oil prices rose.
NDAQ AMD SYF
Amid the selling on Wednesday and even as financials struggled, Capital One Financial (NYSE:COF) did pretty well. While Capital One stock closed lower by 55 basis points, it was able to bounce hard off its lows and hold its ground into the close. Should that inspire confidence among investors?
COF-P COST AXP COF SYF WMT COF-D COF-C COF-F V
2018-08-15 seekingalpha - 7
Berkshire Hathaway increased US Bancorp, Goldman Sachs, Southwest Airlines, and Delta Airlines while reducing Phillips 66.
LBTY PSX THI UAL QSR.WI SIRI MLUSG LBTYK LILAB VRSK BAC BKW UPS USGPF MDLZ SYF TMK BRK.A JNJ BK LILAK VZ BATRA LSXMB WFCNP TMK BATRK LSXMA BATRR VZA STOR BAC CHTR AAPL MON BATRB GM USG QSR DAL WFC FWONB COST LBTYB MA VRSN LBTYA AXTA SNY FWONA V SRG KHC FWONK LSXMK LILA
Synchrony Financial (SYF - Free Report) has announced its extended multi-year collaboration with Lowe’s Companies, Inc. (LOW - Free Report) , highlighting the company’s commitment to provide better valuable benefits as well as various purchasing options to Lowe’s customers. With this partnership extension, Synchrony would be managing and servicing the consumer and commercial credit card programs for Lowe’s customers at more than 1,740 U.
ONDK ATH PYPL SYF
2018-08-14 seekingalpha - 12
The portfolio continues to be heavily concentrated with the top three positions accounting for ~40% of the 13F portfolio.
PCG NSAM.WI CQP PRTK TWX AKBA AR SCACU CAH TRBAB PBF NSAM SLB GE OREX LNG TRBNW VRTV SYF TWC STNL NRF TBPH SCAC SLB MCK OREXQ ATRA SNTL AGN BIIB DIS QRVO GEC NG VSAT ABC CLNY GNE TRCO
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to SYF / Synchrony Financial on message board site Silicon Investor.
|MYSYF: Mercury Scheduling Systems (software)||MYSYF: Mercury Scheduling Systems (software)||MYSYF: Mercury Scheduling Systems (software)|
as of ET